This notice describes how CORELinQ Innovations, LLC , in working with trading partners, business associates and other covered entities’ patient health information, may use and disclose information for business purposes and how authorized parties may be given access to this information. Please review itcarefully.
CORELinQ is legally required to protect the privacy of health information.This information is called “protected health information,” or “PHI” for short,and it includes information that can be used to identify a patient that wereceived about a past, present, or future health or condition, the provision of health care to the patient, or the payment of this health care. We are providing this notice to trading partners, business associates and other covered entities about our privacy practices that explains how, when, and why we use and disclose PHI. With some exceptions, we may not use or disclose any morePHI than is necessary to accomplish the purpose of the use or disclosure. We are legally required to follow the privacy practices that are described in thisnotice and subsequently explained in our Business Associate Agreement (BAA).
However, CORELinQ reserves the right to change the terms of this noticeand our privacy policies at any time. Any changes will apply to the current processes by which we handle PHI today. You can request a copy of this notice by emailing firstname.lastname@example.org
CORELinQ uses and discloses health information for several key reasons. These disclosures are further outlined in the respective Business Associate Contract. Below, we describe the different categories of our uses and disclosures and give some examples of each category.
In any other situation not described in sections IIIA or B above, CORELinQ will ask for written authorization before using or disclosing any trading partners, business associates and other coveredentities’ PHI. This authorization can later be revoked in writing to stop any future uses and disclosures – to the extent that CORELinQ has not taken any action relying on the authorization.
As a business associate, we have and will make available, to those who are authorized to receive it, our business associate agreement (BAA) that further outlines what roles and responsibilities we have to protect our use of PHI in our business duties. For a copy of this BAA, please email rislinq-support@corelinq .com.
If you believe that CORELinQ has violated PHI privacy policies, or you disagree with a decision we have made in handling PHI in the course of doing business, you may file a complaint through our support team at email@example.com. We will conduct a thorough investigation and apply proper resolution measures to address highlighted concerns. You also may send a written complaint to the Secretary of the Department of Health and Human Services at Region VII, Office for Civil Rights, U.S. Department of Healthand Human Services, 601 East 12th Street, Room 248, Kansas City, MO64106 or e-mail at OCRComplaint@hhs.gov or fax at 816/426-3686. No retaliatory action will be taken for such filings. However, if discovery later finds that such filings were made fraudulent, CORELinQ reserves the right to consider and pursue courses of legal action allowable under the law.
If you have any questions about this notice or any complaints about ourprivacy practices, or would like to know how to file a complaint with the Secretary of the Department of Health and Human Services, please email us at: firstname.lastname@example.org
Director, Clinic Services
Dr. A. Joseph Borelli Jr.
President and Medical Director